Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964266 | 0.94 | CNR2 (0.71) | CNR2MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5964676 | 0.86 | CNR2 (0.83) | CNR2MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5963797 | 0.84 | CNR2 (0.53) | CNR2MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL6211710 | 0.82 | MEN1 (0.53) | CNR2MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL6192436 | 0.82 | CNR2 (0.72) | CNR2MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5964161 | 0.82 | CNR2 (0.72) | CNR2MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5964318 | 0.78 | CNR2 (0.60) | CNR2MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5964374 | 0.77 | ADRB1 (0.49) | RORCLMNA | |
| SCHEMBL5963869 | 0.77 | CNR2 (1.00) | CNR2MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5964304 | 0.77 | CNR2 (1.00) | CNR2MEN1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | CNR1, CNR2, OPRL1 | CNR2 2/4885MEN1 4443/4885KMT2A 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.